Shouyao Holdings (beijing) Co. Ltd
Clinical trials sponsored by Shouyao Holdings (beijing) Co. Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug SY-9453 targets Hard-to-Treat cancers in early trial Results expected Feb 2027 (estimated)
-
Fourth-Generation ALK blocker put to the test against resistant cancers
Disease control Recruiting nowResearchers are testing an experimental drug called SY-12321 in adults with advanced cancers that carry an ALK gene change. These include non-small cell lung cancer, inflammatory myofibroblastic tumor, anaplastic large-cell lymphoma, colorectal cancer, pancreatic cancer, and brea…
Phase 1/2 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug SY-9453 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new oral drug, SY-9453, in 122 adults with advanced solid tumors that have a specific genetic deletion (MTAP). The main goals are to check safety, find the best dose, and get a first look at whether the drug can shrink tumors. Participants must…
Phase 1 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC